Immunopathological characterization of ovarian teratomas associated with anti-N-methyl-D-aspartate receptor encephalitis.


Journal

Acta neuropathologica communications
ISSN: 2051-5960
Titre abrégé: Acta Neuropathol Commun
Pays: England
ID NLM: 101610673

Informations de publication

Date de publication:
11 03 2019
Historique:
received: 14 02 2019
accepted: 05 03 2019
entrez: 13 3 2019
pubmed: 13 3 2019
medline: 31 3 2020
Statut: epublish

Résumé

Encephalitis with anti-NMDAR antibodies (NMDAR-E) is a severe autoimmune neurological disorder, defined by a clinical presentation of encephalitis and the presence of IgG targeting the GluN1 subunit of NMDA receptors in the CSF. An underlying ovarian teratoma is commonly associated with this autoimmune disease suggesting a role of the tumor in immunopathogenesis. In this study, we characterized the salient histopathological features of 27 ovarian teratomas associated with NMDAR-E (3 immature and 24 mature teratomas) and 40 controls without associated encephalitis. All but one NMDAR-E-associated teratomas contained a nervous tissue component, while less than 40% of control teratomas did (p < 0.001). GluN1 expression by teratomatous nervous tissue seemed to be more often glial in NMDAR-E teratomas than in control teratomas (73% vs. 29%, p < 0.05). Strikingly, 3 out of 24 NMDAR-E-associated mature teratomas contained neuroglial tissue exhibiting histopathological features of central nervous system neuroglial tumor, while such glioma-like features are exceptionally described in the literature on ovarian teratomas. Moreover, NMDAR-E associated teratomas differed from sporadic ovarian teratomas by consistent and prominent infiltration of the nervous tissue component by immune cells, comprised of T- and B-cells and mature dendritic cells organized in tertiary lymphoid structures, with IgG and IgA deposits and plasma cells in close contact to the neuroglial tissue.These data demonstrate an association between massive infiltration of NMDAR-E-associated teratomas by immune cells and particular glial features of its neuroglial component, suggesting that this glial tissue might be involved in triggering or sustaining the anti-tumor response associated with the auto-immune neurological disease.

Identifiants

pubmed: 30857565
doi: 10.1186/s40478-019-0693-7
pii: 10.1186/s40478-019-0693-7
pmc: PMC6410529
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

38

Subventions

Organisme : Ligue Contre le Cancer
ID : Comité du Rhône
Pays : International
Organisme : Ligue Contre le Cancer
ID : Comité de Savoie
Pays : International
Organisme : Fondation pour la recherche médicale (FR)
ID : DQ20170336751
Pays : International
Organisme : Agence Nationale de la Recherche
ID : ANR-14-CE15-0001-MECANO
Pays : International

Références

Am J Roentgenol Radium Ther Nucl Med. 1969 Nov;107(3):647-51
pubmed: 5357693
Ultrastruct Pathol. 2017 Jan-Feb;41(1):62-66
pubmed: 28029275
Acta Neuropathol. 2009 Dec;118(6):737-43
pubmed: 19680671
Neurol Neuroimmunol Neuroinflamm. 2015 Oct 29;2(6):e166
pubmed: 26568967
Int J Gynecol Pathol. 2012 Sep;31(5):429-37
pubmed: 22833082
Pathol Int. 2018 Dec;68(12):677-684
pubmed: 30427104
Am J Surg Pathol. 1993 Aug;17(8):764-78
pubmed: 8393302
Case Rep Oncol Med. 2014;2014:745462
pubmed: 24744929
JAMA Neurol. 2014 Jun;71(6):717-24
pubmed: 24781184
Acta Neuropathol. 2018 Apr;135(4):569-579
pubmed: 29299667
J Neurol. 2013 Nov;260(11):2831-5
pubmed: 23979101
Pediatr Hematol Oncol. 2010 Nov;27(8):636-40
pubmed: 20863158
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
J Clin Oncol. 2008 Sep 20;26(27):4410-7
pubmed: 18802153
Ann Neurol. 2018 Mar;83(3):553-561
pubmed: 29406578
J Clin Pathol. 2012 Jul;65(7):631-4
pubmed: 22496515
Trends Immunol. 2014 Nov;35(11):571-80
pubmed: 25443495
Acta Obstet Gynecol Scand. 2002 Sep;81(9):896-7
pubmed: 12225310
Eur J Gynaecol Oncol. 1999;20(3):187-8
pubmed: 10410881
Cancer. 1960 Jul-Aug;13:804-11
pubmed: 13838271
PLoS One. 2010 Nov 30;5(11):e14123
pubmed: 21152063
J Neurol. 2018 Oct;265(10):2190-2200
pubmed: 30003358
Lancet Neurol. 2011 Jan;10(1):63-74
pubmed: 21163445
Arch Pathol Lab Med. 2014 Mar;138(3):351-62
pubmed: 24576031
Int J Gynecol Pathol. 2009 Jul;28(4):367-71
pubmed: 19483626
Clin Pharmacol. 2015 Oct 23;7:111-7
pubmed: 26566373
Cancer. 1971 Feb;27(2):343-8
pubmed: 5100397
Histopathology. 1999 Aug;35(2):170-3
pubmed: 10460663
Cereb Cortex. 1999 Mar;9(2):110-20
pubmed: 10220224
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
Eur Neurol. 2014;71(1-2):42-8
pubmed: 24296881
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931

Auteurs

Aude Chefdeville (A)

Institut NeuroMyogène, Equipe Synaptopathies et Autoanticorps (SynatAc), INSERM U1217/UMR CRS 5310, Lyon, France.
University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.

Isabelle Treilleux (I)

Department of Biopathology, Centre Leon Berard, Lyon, France.

Marie-Eve Mayeur (ME)

Institut NeuroMyogène, Equipe Synaptopathies et Autoanticorps (SynatAc), INSERM U1217/UMR CRS 5310, Lyon, France.

Coline Couillault (C)

University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.

Géraldine Picard (G)

French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Lyon, France.

Chloé Bost (C)

Institut NeuroMyogène, Equipe Synaptopathies et Autoanticorps (SynatAc), INSERM U1217/UMR CRS 5310, Lyon, France.
University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Lyon, France.

Karima Mokhtari (K)

Raymond Escourolle Neuropathology Laboratory, Groupement Pitie-Salpetriere, AP-HP, Paris, France.

Alexandre Vasiljevic (A)

University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Department of Pathology, Groupement hospitalier Est, Hospices Civils de Lyon, Lyon, France.

David Meyronet (D)

University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
Department of Pathology, Groupement hospitalier Est, Hospices Civils de Lyon, Lyon, France.

Véronique Rogemond (V)

French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Lyon, France.

Dimitri Psimaras (D)

French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Lyon, France.

Bertrand Dubois (B)

INSERM 1052, CNRS 5286, Centre Leon Berard, Centre de Recherche en Cancérologie de Lyon, Lyon, France.

Jérôme Honnorat (J)

Institut NeuroMyogène, Equipe Synaptopathies et Autoanticorps (SynatAc), INSERM U1217/UMR CRS 5310, Lyon, France.
University of Lyon, Université Claude Bernard Lyon 1, Lyon, France.
French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Lyon, France.
Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69677, Bron Cedex, France.

Virginie Desestret (V)

Institut NeuroMyogène, Equipe Synaptopathies et Autoanticorps (SynatAc), INSERM U1217/UMR CRS 5310, Lyon, France. virginie.desestret@chu-lyon.fr.
University of Lyon, Université Claude Bernard Lyon 1, Lyon, France. virginie.desestret@chu-lyon.fr.
French Reference Center on Paraneoplastic Neurological Syndrome, Hospices Civils de Lyon, Lyon, France. virginie.desestret@chu-lyon.fr.
Hôpital Neurologique Pierre Wertheimer, 59 Boulevard Pinel, 69677, Bron Cedex, France. virginie.desestret@chu-lyon.fr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH